BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Abiraterone decanoate readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Abiraterone decanoate\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07339267-11062@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Abiraterone decanoate: Phase 1 readout est. (NCT07339267)
DESCRIPTION:Abiraterone decanoate\, phase 1\, Prostate Cancer.\nStudy: A St
 udy to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participa
 nts With Prostate Cancer\nEstimated primary completion: 31 October 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/abiraterone-decanoate#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0733
 9267
URL:https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04729114-11062@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Abiraterone decanoate: Phase 1 readout est. (NCT04729114)
DESCRIPTION:Abiraterone decanoate\, phase 1\, Prostate Cancer.\nStudy: A Sa
 fety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate 
 Cancer\nEstimated primary completion: 31 May 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04729114
URL:https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005154-11062@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Abiraterone decanoate: Phase 2 readout est. (NCT07005154)
DESCRIPTION:Abiraterone decanoate\, phase 2\, Prostate Cancer.\nStudy: A Ph
 ase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prosta
 te Cancer\nEstimated primary completion: 31 May 2032. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07005154
URL:https://assetmemo.bio/drug/abiraterone-decanoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
